
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-a68b4900.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-0a3f24ce.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Efficacy and Safety of Tislelizumab as an Immune Checkpoint Inhibitor for the Treatment of Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="4DDE46B889B705531B46B80038DCD68E.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="cureus">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12335811/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Cureus">
<meta name="citation_title" content="Efficacy and Safety of Tislelizumab as an Immune Checkpoint Inhibitor for the Treatment of Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis">
<meta name="citation_author" content="Chao Yuan Li Cai">
<meta name="citation_author_institution" content="General Medicine, Hywel Dda Health Board, Carmarthen, GBR">
<meta name="citation_author" content="Abigail Rai">
<meta name="citation_author_institution" content="Acute Medical Unit, Impur Christian Hospital, Impur, IND">
<meta name="citation_author" content="Hariharasudhan Balaji">
<meta name="citation_author_institution" content="Emergency Medicine, Southern Health and Social Care Trust, Portadown, GBR">
<meta name="citation_author" content="Arvin Raju">
<meta name="citation_author_institution" content="Internal Medicine, Arthur Hospital, Nagapattinam, IND">
<meta name="citation_author" content="Shruthi Murugan">
<meta name="citation_author_institution" content="Bariatric and Minimal Access Surgery, Manipal Hospital Millers Road, Bengaluru, IND">
<meta name="citation_author" content="Shyam Nikethen Girivasan">
<meta name="citation_author_institution" content="Pharmacy, JSS University College of Pharmacy, Ooty, IND">
<meta name="citation_author" content="Samuel Rai">
<meta name="citation_author_institution" content="Medicine, ACS Medical College and Hospital, Chennai, IND">
<meta name="citation_publication_date" content="2025 Jul 10">
<meta name="citation_volume" content="17">
<meta name="citation_issue" content="7">
<meta name="citation_firstpage" content="e87664">
<meta name="citation_doi" content="10.7759/cureus.87664">
<meta name="citation_pmid" content="40786397">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12335811/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12335811/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12335811/pdf/cureus-0017-00000087664.pdf">
<meta name="description" content="Hepatocellular carcinoma (HCC) remains a leading global cause of cancer-related mortality, necessitating effective systemic therapies. Tislelizumab, a novel anti-PD-1 monoclonal antibody, has shown promise in recent trials. However, a pooled ...">
<meta name="og:title" content="Efficacy and Safety of Tislelizumab as an Immune Checkpoint Inhibitor for the Treatment of Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Hepatocellular carcinoma (HCC) remains a leading global cause of cancer-related mortality, necessitating effective systemic therapies. Tislelizumab, a novel anti-PD-1 monoclonal antibody, has shown promise in recent trials. However, a pooled ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12335811/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-testid="header" data-header >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            
                <a class="ncbi-header__logo-container" href="https://www.ncbi.nlm.nih.gov/">
                    <img alt="
                                  NCBI home page
                              "
                         class="ncbi-header__logo-image"
                         src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg" />
                </a>
            

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-testid="searchPanel"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      aria-describedby="search-field-desktop-navigation-help-text"
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only"
                           data-testid="label"
                           for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           data-testid="textInput"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    data-testid="button"
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  role="search">
                <label class="usa-sr-only" for="search-field">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="search" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        <a class="usa-link" href="https://www.ncbi.nlm.nih.gov/pmc/advanced/" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12335811">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.7759/cureus.87664"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/cureus-0017-00000087664.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12335811%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12335811/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12335811/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12335811/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-cureus.png" alt="Cureus logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Cureus" title="Link to Cureus" shape="default" href="http://www.cureus.com/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Cureus</button></div>. 2025 Jul 10;17(7):e87664. doi: <a href="https://doi.org/10.7759/cureus.87664" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.7759/cureus.87664</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Cureus%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cureus%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Cureus%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Cureus%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Efficacy and Safety of Tislelizumab as an Immune Checkpoint Inhibitor for the Treatment of Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20Cai%20CY%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Chao Yuan Li Cai</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Chao Yuan Li Cai</span></h3>
<div class="p">
<sup>1</sup>
General Medicine, Hywel Dda Health Board, Carmarthen, GBR </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20Cai%20CY%22%5BAuthor%5D" class="usa-link"><span class="name western">Chao Yuan Li Cai</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Rai%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Abigail Rai</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Abigail Rai</span></h3>
<div class="p">
<sup>2</sup>
Acute Medical Unit, Impur Christian Hospital, Impur, IND </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Rai%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Abigail Rai</span></a>
</div>
</div>
<sup>2,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Balaji%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Hariharasudhan Balaji</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Hariharasudhan Balaji</span></h3>
<div class="p">
<sup>3</sup>
Emergency Medicine, Southern Health and Social Care Trust, Portadown, GBR </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Balaji%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">Hariharasudhan Balaji</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Raju%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Arvin Raju</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Arvin Raju</span></h3>
<div class="p">
<sup>4</sup>
Internal Medicine, Arthur Hospital, Nagapattinam, IND </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Raju%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Arvin Raju</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Murugan%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Shruthi Murugan</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Shruthi Murugan</span></h3>
<div class="p">
<sup>5</sup>
Bariatric and Minimal Access Surgery, Manipal Hospital Millers Road, Bengaluru, IND </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Murugan%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Shruthi Murugan</span></a>
</div>
</div>
<sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Girivasan%20SN%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Shyam Nikethen Girivasan</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Shyam Nikethen Girivasan</span></h3>
<div class="p">
<sup>6</sup>
Pharmacy, JSS University College of Pharmacy, Ooty, IND </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Girivasan%20SN%22%5BAuthor%5D" class="usa-link"><span class="name western">Shyam Nikethen Girivasan</span></a>
</div>
</div>
<sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Rai%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Samuel Rai</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Samuel Rai</span></h3>
<div class="p">
<sup>7</sup>
Medicine, ACS Medical College and Hospital, Chennai, IND </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Rai%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Samuel Rai</span></a>
</div>
</div>
<sup>7</sup>
</div>
<div class="cg p">Editors: <span class="name western">Alexander Muacevic</span>, <span class="name western">John R Adler</span>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="aff-1">
<sup>1</sup>
General Medicine, Hywel Dda Health Board, Carmarthen, GBR </div>
<div id="aff-2">
<sup>2</sup>
Acute Medical Unit, Impur Christian Hospital, Impur, IND </div>
<div id="aff-3">
<sup>3</sup>
Emergency Medicine, Southern Health and Social Care Trust, Portadown, GBR </div>
<div id="aff-4">
<sup>4</sup>
Internal Medicine, Arthur Hospital, Nagapattinam, IND </div>
<div id="aff-5">
<sup>5</sup>
Bariatric and Minimal Access Surgery, Manipal Hospital Millers Road, Bengaluru, IND </div>
<div id="aff-6">
<sup>6</sup>
Pharmacy, JSS University College of Pharmacy, Ooty, IND </div>
<div id="aff-7">
<sup>7</sup>
Medicine, ACS Medical College and Hospital, Chennai, IND </div>
<div class="author-notes p">
<div class="fn" id="cor1">
<sup>✉</sup><p class="display-inline">
Abigail Rai <span>abigailrai34@gmail.com</span>
</p>
</div>
<div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Accepted 2025 Jul 10; Collection date 2025 Jul.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>Copyright © 2025, Li Cai et al.</div>
<p>This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12335811  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40786397/" class="usa-link">40786397</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<p>Hepatocellular carcinoma (HCC) remains a leading global cause of cancer-related mortality, necessitating effective systemic therapies. Tislelizumab, a novel anti-PD-1 monoclonal antibody, has shown promise in recent trials. However, a pooled assessment of its clinical efficacy and safety in HCC treatment has been lacking. To systematically evaluate and quantify the efficacy and safety of tislelizumab in HCC, focusing on key outcomes including overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and treatment-related adverse events (TRAEs), a systematic search of PubMed, Scopus, Cochrane Library, ScienceDirect, the American Society of Clinical Oncology (ASCO), and the European Society of Medical Oncology (ESMO) databases was conducted for clinical trials from January 2010 to October 2024. Seven studies involving 1,178 patients were included in the analysis. Statistical analyses were performed using the Comprehensive Meta-Analysis software (version 3.7). Fixed-effect and random-effects models were used based on heterogeneity (I² statistic), and publication bias was assessed using Egger's and Begg's tests, alongside Duval and Tweedie's trim-and-fill method. The pooled ORR was estimated at 22.3% (logit = -1.242; SE = 0.0897), but after correcting for publication bias (Egger's p = 0.027), the adjusted ORR decreased to 17.2%. The pooled OS was 13.66 months (95% CI: 11.97-15.35) with no heterogeneity (I² = 0%), affirming the robustness of the survival benefit. PFS was 4.58 months under a fixed-effect model but increased to 5.86 months with the random-effects model due to high heterogeneity (I² = 93.15%). The incidence of Grade ≥ 3 TRAEs was 28.9% (logit = -0.448), indicating a manageable safety profile, with no significant publication bias (Egger's p = 0.251). Tislelizumab demonstrates favorable clinical activity in HCC, offering meaningful improvements in survival and disease control with acceptable toxicity. While ORR results were influenced by potential publication bias, survival and safety outcomes were consistent and reliable. These findings support tislelizumab as a viable immunotherapeutic option for advanced HCC, warranting further exploration in larger, randomized trials and combination therapy regimens to optimize patient outcomes.</p>
<section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> hepatocellular carcinoma (hcc), immune checkpoint inhibitors, objective response rate, progression-free survival (pfs), systematic review and meta-analysis</p></section></section><section id="sec1"><h2 class="pmc_sec_title">Introduction and background</h2>
<p>Hepatocellular carcinoma (HCC) is the most common primary liver tumor and the fifth most common cancer worldwide, constituting over 90% of liver cancers and predominantly occurring in patients with cirrhosis, carrying an annual HCC incidence of 2-4%, and having a dismal five-year survival rate of 18% [<a href="#REF1" class="usa-link" aria-describedby="REF1">1</a>]. Key etiology includes chronic viral hepatitis (hepatitis B and C), alcoholic liver disease, and non-alcoholic steatohepatitis/non-alcoholic fatty liver disease, emphasizing the critical need for early detection and management [<a href="#REF2" class="usa-link" aria-describedby="REF2">2</a>]. Cirrhosis plays a pivotal role in viral carcinogenesis for HCC, driven by hepatitis B virus genome integration into telomerase reverse transcriptase promoter sites and genetic mutations (e.g., <em>TP53</em>, <em>CTNNB1</em>, <em>ARID1A</em>), while chronic hepatitis C virus infection contributes through inflammation, fibrosis, and viral proteins, predominantly in cirrhotic or advanced fibrosis cases [<a href="#REF1" class="usa-link" aria-describedby="REF1">1</a>,<a href="#REF3" class="usa-link" aria-describedby="REF3">3</a>].</p>
<p>The advent of immunotherapies targeting the programmed death receptor-1 (PD-1) pathway has transformed the treatment landscape of various solid tumors [<a href="#REF4" class="usa-link" aria-describedby="REF4">4</a>]. Tislelizumab, a humanized anti-PD-1 monoclonal antibody, is designed to minimize binding to Fcγ receptors on macrophages, exhibiting high affinity and prolonged receptor engagement. Its unique binding properties enhance its inhibitory effects on PD-1/PD-L1 signaling, potentially improving anti-tumor immune responses [<a href="#REF5" class="usa-link" aria-describedby="REF5">5</a>-<a href="#REF7" class="usa-link" aria-describedby="REF7">7</a>].</p>
<p>Tislelizumab has demonstrated a favorable safety profile and manageable treatment-related adverse events (TRAEs) across multiple clinical trials in non-HCC solid tumors, showing effectiveness in treating advanced lung cancer [<a href="#REF8" class="usa-link" aria-describedby="REF8">8</a>], non-small cell lung cancer (NSCLC) subtypes [<a href="#REF9" class="usa-link" aria-describedby="REF9">9</a>], and EGFR + TP53 co-variant lung adenocarcinoma [<a href="#REF10" class="usa-link" aria-describedby="REF10">10</a>], both as monotherapy and in combination with chemotherapy, supporting the drug's general immunotherapeutic potential. Its efficacy is highlighted by improved health-related quality of life, superior clinical outcomes, and cost-effectiveness compared to standard chemotherapy, making it a promising treatment option despite limitations in the generalizability and heterogeneity of current trial data [<a href="#REF11" class="usa-link" aria-describedby="REF11">11</a>]. Tislelizumab received its first regulatory approval from China's National Medical Products Administration (NMPA) in December 2019 for relapsed or refractory classical Hodgkin's lymphoma [<a href="#REF7" class="usa-link" aria-describedby="REF7">7</a>], followed by approvals for metastatic urothelial carcinoma with high PD-L1 expression in 2020 [<a href="#REF12" class="usa-link" aria-describedby="REF12">12</a>] and for NSCLC (with chemotherapy) and hepatocellular carcinoma (as monotherapy) in 2021 [<a href="#REF13" class="usa-link" aria-describedby="REF13">13</a>]. Additionally, applications for second-line NSCLC therapy and MSI-H/dMMR solid tumors have been accepted, highlighting tislelizumab's expanding indications and promising anti-tumor efficacy [<a href="#REF5" class="usa-link" aria-describedby="REF5">5</a>]. Several clinical trials [<a href="#REF9" class="usa-link" aria-describedby="REF9">9</a>,<a href="#REF14" class="usa-link" aria-describedby="REF14">14</a>-<a href="#REF16" class="usa-link" aria-describedby="REF16">16</a>] have shown promising results in the efficacy and safety of tislelizumab for the treatment of HCC; however, there is no meta-analysis analyzing the pooled outcomes to measure its efficacy in this particular disease condition.</p>
<p>Aims and objectives</p>
<p>This study aims to systematically evaluate and assess the efficacy and safety of tislelizumab as an immune checkpoint inhibitor in the treatment of HCC. Thus, the primary objective of this study was to systematically evaluate and quantify the efficacy and safety of tislelizumab, a PD-1 inhibitor, in the treatment of HCC by synthesizing data from clinical trials. Given the rising interest in immune checkpoint inhibitors for HCC and the emergence of tislelizumab as a promising agent, this meta-analysis aimed to generate pooled estimates for key clinical outcomes, including objective response rate (ORR), overall survival (OS), progression-free survival (PFS), and TRAEs. This study aims to provide a comprehensive understanding of tislelizumab's therapeutic potential, highlighting its effectiveness in improving clinical outcomes and addressing safety concerns in patients with HCC.</p></section><section id="sec2"><h2 class="pmc_sec_title">Review</h2>
<p>Methodology</p>
<p>This study was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [<a href="#REF17" class="usa-link" aria-describedby="REF17">17</a>] for conducting this systematic review and meta-analysis.</p>
<p>Search Strategy</p>
<p>Two reviewers comprehensively searched for eligible studies from MEDLINE (PubMed), Central (Cochrane Library), Scopus, ScienceDirect, the American Society of Clinical Oncology (ASCO), and the European Society of Medical Oncology (ESMO) databases from January 2010 to October 2024, focusing on randomized controlled trials (RCTs) and clinical trials identifying the efficacy and safety assessment of tislelizumab. Table <a href="#TAB1" class="usa-link">1</a> provides a detailed description of the keywords with Boolean operators used for each database. No language restriction was applied. The reference lists of all eligible trials were also searched to identify other studies. Duplicate studies were eliminated using EndNote 20.2.1 (Clarivate Analytics, Philadelphia, PA). The electronic databases PubMed and Cochrane Library were selected for their extensive coverage of clinical and systematic reviews, providing relevant peer-reviewed studies on imaging techniques.</p>
<section class="tw xbox font-sm" id="TAB1"><h3 class="obj_head">Table 1. Search strategy employed.</h3>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups"><tbody>
<tr style="background-color:#ccc">
<td rowspan="1" colspan="1">Database</td>
<td rowspan="1" colspan="1">Search Terms</td>
</tr>
<tr>
<td rowspan="1" colspan="1">PubMed</td>
<td rowspan="1" colspan="1">(("Tislelizumab"[Title/Abstract] OR "BGB-A317"[Title/Abstract] OR "anti-PD-1 antibody"[Title/Abstract] OR "anti-PD-1 therapy"[Title/Abstract]) AND ("hepatocellular carcinoma"[Title/Abstract] OR "liver cancer"[Title/Abstract] OR "HCC"[Title/Abstract])) AND (clinicaltrial[Filter] OR randomizedcontrolledtrial[Filter])</td>
</tr>
<tr style="background-color:#ccc">
<td rowspan="1" colspan="1">Cochrane Library</td>
<td rowspan="1" colspan="1">(Tislelizumab) AND (hepatocellular carcinoma OR liver cancer OR HCC)</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Scopus</td>
<td rowspan="1" colspan="1">( TITLE-ABS-KEY ( tislelizumab ) AND TITLE-ABS-KEY ( "hepatocellular carcinoma" OR HCC ) AND TITLE-ABS-KEY ( "treatment-related adverse events" OR TRAEs ) )</td>
</tr>
<tr style="background-color:#ccc">
<td rowspan="1" colspan="1">ScienceDirect</td>
<td rowspan="1" colspan="1">( tislelizumab ) AND ( "hepatocellular carcinoma" OR HCC ) AND ( "treatment-related adverse events" OR TRAEs )</td>
</tr>
<tr>
<td rowspan="1" colspan="1">American Society of Clinical Oncology (ASCO)</td>
<td rowspan="1" colspan="1">"tislelizumab" AND "Hepatocellular carcinoma"</td>
</tr>
<tr style="background-color:#ccc">
<td rowspan="1" colspan="1">European Society of Medical Oncology (ESMO)</td>
<td rowspan="1" colspan="1">"tislelizumab"</td>
</tr>
</tbody></table></div>
<div class="p text-right font-secondary"><a href="table/TAB1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><p>Study Selection</p>
<p>The study selection criteria for this meta-analysis followed the SPIDER framework to accommodate both single-arm and comparative studies assessing tislelizumab for HCC. The sample included adult patients (≥18 years) with a confirmed diagnosis of HCC at any stage (early, intermediate, or advanced). The phenomenon of interest focused on evaluating the clinical efficacy and safety of tislelizumab, including outcomes such as OS, PFS, ORR, and TRAEs. Studies with various designs, such as RCTs, prospective or retrospective cohort studies, and single-arm trials, were included to capture a broad spectrum of clinical evidence. The evaluation centered on studies reporting at least one predefined outcome, with data presented as event rates, hazard ratios (HR), means and standard deviations (SD), or proportions. Both comparative studies (e.g., tislelizumab vs. placebo or standard therapies) and single-arm studies providing sufficient outcome data were eligible for inclusion. The framework emphasized research types focused on quantitative studies that report survival outcomes or adverse event proportions. Reviews, case reports, editorials, conference abstracts, and studies without relevant outcome data were excluded. The SPIDER framework facilitated comprehensive and flexible study selection, allowing for the inclusion of diverse study designs and data to evaluate the efficacy and safety of tislelizumab in HCC treatment.</p>
<p>Data Collection and Quality Evaluation</p>
<p>Two reviewers independently assessed the papers on EndNote 20.2.1 based on their titles and abstracts, in accordance with the qualifying requirements. EndNote 20.2.1 was chosen for title and abstract screening due to its efficient reference management capabilities and automatic duplicate detection, which streamlined the initial study selection process. The full texts of the remaining papers were separately reviewed, and disagreements were resolved by a third, blinded reviewer who independently made a final decision on disputed studies, ensuring an unbiased resolution process.</p>
<p>The following information was retrieved from the studies using a piloted Microsoft Excel (Microsoft Corporation, Redmond, Washington) sheet: the first author's surname with year of publication, country of study, study design, diagnosis of the cohort, number of participants (n), mean age with female count and percentage, clinical interventions used, and measured outcomes. Microsoft Excel was used for data extraction due to its flexibility in organizing multiple categories and filtering data, which allowed for detailed categorization across study characteristics and outcomes. The data extraction sheet in Excel was pre-tested with a sample of studies to ensure consistency in data entry and category definitions. The sheet included key categories such as author, publication year, study design, sample size, mean age, diagnostic outcomes, and quality assessment scores. Additionally, specific columns were dedicated to quality notes, enabling systematic documentation of methodological rigor and potential sources of bias. The study quality was scaled. The quality of evidence for each included study was evaluated using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach [<a href="#REF18" class="usa-link" aria-describedby="REF18">18</a>]. This framework assesses evidence based on factors including study design, risk of bias, inconsistency, indirectness, imprecision, and potential publication bias. Each study was assigned a certainty rating: high, moderate, low, or very low, depending on its methodological rigor and relevance to the research question.</p>
<p>For the included RCTs, the Cochrane Risk of Bias 2 (Rob2) tool [<a href="#REF19" class="usa-link" aria-describedby="REF19">19</a>] was used for assessing the risk of bias whereby studies were assessed based on the following five domains: (i) the randomization process; (ii) deviations from intended interventions; (iii) missing outcome data; (iv) measurement of the outcome; and (v) selection of the reported result. For the included observational or cohort studies, the Cochrane Risk of Bias in Non-Randomized Studies - of Interventions (ROBINS-I) tool [<a href="#REF20" class="usa-link" aria-describedby="REF20">20</a>] was used, where the studies were assessed based on the seven domains of confounding, selection of participants, classification of interventions, deviations from intended interventions, missing data, measurement of outcomes, and selection of reported results. The results were represented through traffic light plots and summary bar charts using the Cochrane Risk-of-bias VISualization (Robvis) tool [<a href="#REF21" class="usa-link" aria-describedby="REF21">21</a>]. In the traffic light plot, green, yellow, and red indicators represented low, moderate, and high risk of bias, respectively, across domains. Expected findings included a low to moderate risk of bias in most domains, with occasional high bias in participant selection. Bar charts summarized these findings, highlighting areas where specific biases were prevalent across studies. To mitigate potential biases, we employed rigorous inclusion criteria, ensured consistency in data extraction, and performed sensitivity analyses wherever feasible.</p>
<p>Statistical Analysis</p>
<p>The statistical analysis was performed using Comprehensive Meta-Analysis (CMA) software, version 3.7, which facilitated the estimation of pooled effects under both fixed-effects and random-effects models. The fixed-effect model was initially applied to provide a weighted average effect, assuming homogeneity across studies. In contrast, the random-effects model was subsequently employed when heterogeneity was detected, allowing for between-study variance and ensuring a more conservative estimate. Specifically, fixed and random models were used for ORR, OS, PFS, and TRAEs, depending on heterogeneity metrics. Heterogeneity was assessed using Cochran's Q statistic and I² index, where I² values above 50% indicated moderate to high heterogeneity. For ORR (I² = 89.93%), PFS (I² = 93.15%), and TRAEs (I² = 97.2%), high heterogeneity justified the use of the random-effects model. In contrast, OS showed no significant heterogeneity (I² = 0%), validating the fixed-effect model. To evaluate publication bias, the analysis incorporated several tests: Begg and Mazumdar's rank correlation (Kendall's tau-b), Egger's regression intercept test, and Duval and Tweedie's trim-and-fill method. ORR exhibited evidence of publication bias (Egger's p = 0.027), while OS, PFS, and TRAEs did not. Fail-safe N and Orwin's fail-safe N further assessed the robustness of pooled estimates by estimating the number of missing null studies required to nullify observed effects. Collectively, this methodological framework ensured a rigorous and statistically sound evaluation of tislelizumab's clinical outcomes across diverse studies.</p>
<p>Results</p>
<p>PRISMA Compliance</p>
<p>The PRISMA flowchart in Figure <a href="#FIG1" class="usa-link">1</a> visually represents the systematic process of literature identification, screening, eligibility assessment, and inclusion for this meta-analysis on tislelizumab in HCC. A total of 277 records were identified through six major databases, including PubMed (n=17), Cochrane Library (n=48), Scopus (n=53), ScienceDirect (n=134), ASCO (n=17), and ESMO (n=8). Prior to screening, 83 records were removed, comprising 58 duplicates and 25 non-scientific sources, including news reports and non-peer-reviewed content. After these exclusions, 194 records were screened, all of which were considered for full-text retrieval. A total of 131 full-text reports could not be retrieved, leaving 63 studies to be assessed for eligibility. Of these, 56 studies were excluded, as 23 were not related to HCC, 21 presented non-measurable results, and 12 lacked sufficient methodological clarity or data. This process resulted in the inclusion of seven studies in both the qualitative synthesis and final review. No additional studies were excluded for reporting on overlapping populations.</p>
<figure class="fig xbox font-sm" id="FIG1"><h3 class="obj_head">Figure 1. PRISMA flowchart.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12335811_cureus-0017-00000087664-i01.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9231/12335811/2384b1b52894/cureus-0017-00000087664-i01.jpg" loading="lazy" height="953" width="750" alt="Figure 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/FIG1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses</p></figcaption></figure><p>Study Characteristics</p>
<p>The included studies in this systematic review represent a diverse range of clinical designs and populations evaluating tislelizumab in the treatment of HCC, as shown in Table <a href="#TAB2" class="usa-link">2</a>. A total of seven studies were analyzed, encompassing RCTs, phase I/II single-arm trials, and multicenter studies. The sample sizes ranged from 20 to 674 patients, with varying age distributions (mean age between 52.5 and 62 years) and a predominantly male population, reflecting the epidemiology of HCC. Most studies have focused on advanced or unresectable HCC, with some investigating tislelizumab as monotherapy, while others have assessed it in combination with agents such as radiotherapy, lenvatinib, or bevacizumab biosimilars. Geographically, the majority of studies were conducted in China, while two were global or multi-regional in scope.</p>
<section class="tw xbox font-sm" id="TAB2"><h3 class="obj_head">Table 2. Study characteristic table.</h3>
<div class="caption p"><p>HCC: hepatocellular carcinoma; ORR: objective response rate; CR: complete response; PR: Partial response; SD: stable disease; PD: progressive disease; DCR: disease control rate; OS: overall survival; PFS: progression-free survival; AE: adverse events; pRR: pathological response rate; pCR: pathological complete response; MPR: major pathological response; RFS: recurrence-free survival; SBRT: stereotactic body radiotherapy; IMRT: intensity-modulated radiotherapy; uHCC: unresectable hepatocellular carcinoma</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups"><tbody>
<tr style="background-color:#ccc">
<td rowspan="1" colspan="1">Study</td>
<td rowspan="1" colspan="1">Country</td>
<td rowspan="1" colspan="1">Design</td>
<td rowspan="1" colspan="1">Diagnosis</td>
<td rowspan="1" colspan="1">Patient Count</td>
<td rowspan="1" colspan="1">Mean Age (Years)</td>
<td rowspan="1" colspan="1">Female % (n)</td>
<td rowspan="1" colspan="1">Intervention</td>
<td rowspan="1" colspan="1">Outcomes Reported</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Ren et al. 2022 [<a href="#REF22" class="usa-link" aria-describedby="REF22">22</a>]</td>
<td rowspan="1" colspan="1">Eight countries in Europe and Asia</td>
<td rowspan="1" colspan="1">Non-randomized, multicenter, open-label phase 2</td>
<td rowspan="1" colspan="1">Advanced HCC</td>
<td rowspan="1" colspan="1">249</td>
<td rowspan="1" colspan="1">62</td>
<td rowspan="1" colspan="1">12.9% (32)</td>
<td rowspan="1" colspan="1">Tislelizumab 200 mg i.v. every 3 weeks, on day 1 of each 21-day cycle</td>
<td rowspan="1" colspan="1">ORR, duration of response, DCR, OS, AE</td>
</tr>
<tr style="background-color:#ccc">
<td rowspan="1" colspan="1">Qin et al. 2023 [<a href="#REF23" class="usa-link" aria-describedby="REF23">23</a>]</td>
<td rowspan="1" colspan="1">Global, multiregional</td>
<td rowspan="1" colspan="1">Open-label, phase 3, randomized clinical trial</td>
<td rowspan="1" colspan="1">HCC</td>
<td rowspan="1" colspan="1">674</td>
<td rowspan="1" colspan="1">61</td>
<td rowspan="1" colspan="1">15.4% (104)</td>
<td rowspan="1" colspan="1">Tislelizumab, 200 mg intravenously every 3 weeks vs. sorafenib tosylate, 400 mg orally twice daily</td>
<td rowspan="1" colspan="1">OS, ORR, PFS, duration of response, AE</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Ren et al. 2023 [<a href="#REF24" class="usa-link" aria-describedby="REF24">24</a>]</td>
<td rowspan="1" colspan="1">China</td>
<td rowspan="1" colspan="1">Phase 2, randomized open-label study</td>
<td rowspan="1" colspan="1">HCC</td>
<td rowspan="1" colspan="1">94</td>
<td rowspan="1" colspan="1">58.5</td>
<td rowspan="1" colspan="1">NA</td>
<td rowspan="1" colspan="1">Ociperlimab (OCI) + tislelizumab (TIS) + BAT1706 (bevacizumab biosimilar) versus TIS + BAT1706</td>
<td rowspan="1" colspan="1">OR, CR, PR, SD, PD, ORR, PFS, duration of response, AE</td>
</tr>
<tr style="background-color:#ccc">
<td rowspan="1" colspan="1">Li Z et al. 2023 [<a href="#REF25" class="usa-link" aria-describedby="REF25">25</a>]</td>
<td rowspan="1" colspan="1">China</td>
<td rowspan="1" colspan="1">Single-center phase 1b</td>
<td rowspan="1" colspan="1">Early-stage HCC</td>
<td rowspan="1" colspan="1">20</td>
<td rowspan="1" colspan="1">58.5</td>
<td rowspan="1" colspan="1">NA</td>
<td rowspan="1" colspan="1">SBRT plus tislelizumab</td>
<td rowspan="1" colspan="1">ORR, pRR, pCR, AE</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Li J et al. 2024 [<a href="#REF26" class="usa-link" aria-describedby="REF26">26</a>]</td>
<td rowspan="1" colspan="1">China</td>
<td rowspan="1" colspan="1">Single-center, single-arm, phase II clinical trial</td>
<td rowspan="1" colspan="1">Advanced HCC</td>
<td rowspan="1" colspan="1">47</td>
<td rowspan="1" colspan="1">53</td>
<td rowspan="1" colspan="1">10.6% (5)</td>
<td rowspan="1" colspan="1">Sitravatinib ± tislelizumab</td>
<td rowspan="1" colspan="1">OR, DCR, OS, PFS, AE</td>
</tr>
<tr style="background-color:#ccc">
<td rowspan="1" colspan="1">Pan et al. 2024 [<a href="#REF27" class="usa-link" aria-describedby="REF27">27</a>]</td>
<td rowspan="1" colspan="1">China</td>
<td rowspan="1" colspan="1">Single-arm, phase 2 trial</td>
<td rowspan="1" colspan="1">Advanced HCC with macrovascular invasion</td>
<td rowspan="1" colspan="1">30</td>
<td rowspan="1" colspan="1">NA</td>
<td rowspan="1" colspan="1">13.3% (4)</td>
<td rowspan="1" colspan="1">Tislelizumab plus IMRT</td>
<td rowspan="1" colspan="1">ORR, OS, pCR/MPR, RFS, AE</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Xu et al. 2024 [<a href="#REF28" class="usa-link" aria-describedby="REF28">28</a>]</td>
<td rowspan="1" colspan="1">China</td>
<td rowspan="1" colspan="1">Prospective, multicenter, open-label, single-arm, phase 2 study</td>
<td rowspan="1" colspan="1">Systemic treatment-naïve patients with uHCC</td>
<td rowspan="1" colspan="1">64</td>
<td rowspan="1" colspan="1">52.5</td>
<td rowspan="1" colspan="1">17.2% (11)</td>
<td rowspan="1" colspan="1">Tislelizumab plus lenvatinib</td>
<td rowspan="1" colspan="1">ORR, CR, PR, DCR, AE</td>
</tr>
</tbody></table></div>
<div class="p text-right font-secondary"><a href="table/TAB2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><p>GRADE Assessment</p>
<p>The study by Qin et al. (2023) [<a href="#REF23" class="usa-link" aria-describedby="REF23">23</a>] was a phase III RCT comparing tislelizumab to sorafenib. It was the only study rated as high-quality evidence according to the GRADE framework due to its robust design and sample size. In contrast, early-phase single-arm studies, including Ren et al. (2022) [<a href="#REF22" class="usa-link" aria-describedby="REF22">22</a>], Li et al. (2023) [<a href="#REF25" class="usa-link" aria-describedby="REF25">25</a>], and Pan et al. (2024) [<a href="#REF27" class="usa-link" aria-describedby="REF27">27</a>], were rated as very low to low quality due to small sample sizes, lack of control groups, and indirect applicability to broader HCC populations. Intermediate-quality evidence was derived from Ren et al. (2023) [<a href="#REF24" class="usa-link" aria-describedby="REF24">24</a>] and Xu et al. (2024) [<a href="#REF28" class="usa-link" aria-describedby="REF28">28</a>], which, despite their moderate designs, had limitations related to imprecision and indirectness. The full GRADE assessment of each study, outlining factors such as risk of bias and consistency, is detailed as a supplementary table in the Appendices (Table <a href="#TAB3" class="usa-link">3</a>). This characterization facilitates the interpretation of pooled outcomes and highlights the need for caution when generalizing findings from lower-certainty evidence.</p>
<p>Risk of Bias Assessment</p>
<p>The risk of bias across seven domains for the five non-randomized cohort studies indicates an overall moderate risk, as depicted in Figure <a href="#FIG2" class="usa-link">2</a>. Moderate risks were noted in confounding (D1) for Li et al. [<a href="#REF25" class="usa-link" aria-describedby="REF25">25</a>] and Ren et al. [<a href="#REF22" class="usa-link" aria-describedby="REF22">22</a>], primarily due to inadequate adjustment for critical variables, such as tumor stage, prior treatments, or patient comorbidities, which could potentially skew the outcomes. Similarly, the selection of participants (D2) posed a moderate risk in Li et al. [<a href="#REF25" class="usa-link" aria-describedby="REF25">25</a>], Pan et al. [<a href="#REF27" class="usa-link" aria-describedby="REF27">27</a>], and Ren et al. [<a href="#REF22" class="usa-link" aria-describedby="REF22">22</a>], likely due to non-randomized designs and imbalanced baseline characteristics, which limited cohort comparability. All studies exhibited a moderate risk in outcome measurement (D6) due to the subjective nature of certain outcomes, such as tumor response or adverse event severity, which may not have been assessed in a blinded manner, potentially leading to observer bias. Additionally, selective reporting (D7) was evident across all studies, raising concerns about transparency as non-significant or unfavorable results may have been excluded. Conversely, the studies demonstrated low risk in intervention classification (D3), deviations from interventions (D4), and missing data (D5), reflecting sound methodological execution in these domains. The overall moderate risk of bias underscores the need for future studies to implement rigorous design measures, such as randomization or propensity score matching, blinded outcome assessments, and pre-registration of study protocols, to ensure robust and reliable evaluation of tislelizumab's efficacy and safety in hepatocellular carcinoma.</p>
<figure class="fig xbox font-sm" id="FIG2"><h3 class="obj_head">Figure 2. Risk of bias of the included non-randomized studies.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12335811_cureus-0017-00000087664-i02.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9231/12335811/59d7e28c0dd7/cureus-0017-00000087664-i02.jpg" loading="lazy" height="525" width="750" alt="Figure 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/FIG2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure><p>The risk of bias assessment in Figure <a href="#FIG3" class="usa-link">3</a> for the studies "Qin et al. (2023) [<a href="#REF23" class="usa-link" aria-describedby="REF23">23</a>]" and "Ren et al. (2023) [<a href="#REF24" class="usa-link" aria-describedby="REF24">24</a>]" highlights several methodological strengths and limitations. Qin et al. (2023) demonstrated a low risk of bias in domains related to the randomization process (D1), outcome measurement (D4), and selection of reported results (D5). However, there were "some concerns" regarding deviations from intended interventions (D2), potentially indicating minor protocol inconsistencies, and missing outcome data (D3), which may suggest incomplete follow-ups or insufficient data handling. The overall risk of bias for this study was deemed "some concerns." Ren et al. (2023) [<a href="#REF24" class="usa-link" aria-describedby="REF24">24</a>], similarly, showed a low risk in D1 and D5, confirming proper randomization and comprehensive reporting. However, it presented a high risk of bias in D2 due to significant deviations from the intended interventions, which could potentially impact the study's validity. Additionally, "some concerns" were noted for D3 and D4, reflecting issues such as incomplete data and subjective measurements. Overall, while both studies provide valuable insights into tislelizumab's efficacy, concerns about deviations from interventions, missing data, and subjective assessments underscore the need for cautious interpretation of their findings.</p>
<figure class="fig xbox font-sm" id="FIG3"><h3 class="obj_head">Figure 3. Risk of bias of the included randomized controlled studies.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12335811_cureus-0017-00000087664-i03.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9231/12335811/003c6bdf34f2/cureus-0017-00000087664-i03.jpg" loading="lazy" height="302" width="750" alt="Figure 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/FIG3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure><p>Objective Response Rate</p>
<p>The forest plot in Figure <a href="#FIG4" class="usa-link">4</a> evaluates the ORR of tislelizumab in treating HCC by synthesizing data from six studies. The fixed-effect model yielded a pooled logit effect size of -1.242 (standard error = 0.0897), corresponding to an estimated ORR of approximately 22.3%, indicating that the response rate to tislelizumab across these studies remains modest but clinically relevant. A logit value of -1.242 translates to a probability of response of 0.223, meaning that approximately 22.3% of patients with HCC responded to the drug. Key contributors to this overall effect include studies by Qin et al. (2023) [<a href="#REF23" class="usa-link" aria-describedby="REF23">23</a>] and Ren et al. (2023) [<a href="#REF22" class="usa-link" aria-describedby="REF22">22</a>], both showing more pronounced negative logits (less favorable response), with logit values of -1.79 and -1.91, respectively, and associated p-values of 0, indicating statistically significant effects. Conversely, Li et al. (2024) [<a href="#REF26" class="usa-link" aria-describedby="REF26">26</a>] and Xu et al. (2024) [<a href="#REF28" class="usa-link" aria-describedby="REF28">28</a>] reported smaller logit values with wider confidence intervals, indicating a lower impact and variability. Importantly, heterogeneity across studies is high, as indicated by an I² of 89.93% and a significant Q-value (59.56, p &lt; 0.0001), suggesting considerable variability not due to chance. The random-effects model, adjusting for this heterogeneity, yielded a slightly less negative pooled logit of -0.920, translating to a higher ORR (~28.5%). Clinically, the findings suggest tislelizumab offers a modest but consistent therapeutic benefit for HCC patients, albeit with variability influenced by study design, population, or tumor characteristics. This supports its role as a viable immunotherapy option while underscoring the need for personalized treatment strategies and further stratified research to optimize response.</p>
<figure class="fig xbox font-sm" id="FIG4"><h3 class="obj_head">Figure 4. Forest plot depicting objective response rate (ORR).</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12335811_cureus-0017-00000087664-i04.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9231/12335811/2dc317b0d9d7/cureus-0017-00000087664-i04.jpg" loading="lazy" height="343" width="750" alt="Figure 4"></a></p>
<div class="p text-right font-secondary"><a href="figure/FIG4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>O+T+B: ociperlimab (O) + tislelizumab (T) + BAT1706 (B); T+B: tislelizumab (TIS) + BAT1706 (B); CI: confidence interval</p></figcaption></figure><p>Overall Survival</p>
<p>The forest plot in Figure <a href="#FIG5" class="usa-link">5</a> evaluates the OS outcome of tislelizumab in patients with HCC, based on four included studies. The fixed-effect and random-effects models yielded an identical pooled effect size of 13.66 months (SE = 0.863), with a 95% confidence interval ranging from 11.97 to 15.35 months. The point estimate of 13.66 months represents the average overall survival duration following tislelizumab treatment, indicating that the drug provides a meaningful survival benefit in advanced HCC populations. The analysis revealed no significant heterogeneity across studies (Q = 2.50, df = 3, p = 0.476), with an I² of 0%, suggesting that the variation in outcomes is likely due to chance rather than study-level differences. Additionally, Tau² = 0, confirming the robustness of the findings across studies. The Z-value of 15.83 (p &lt; 0.001) supports that the observed pooled effect is highly statistically significant. Among the individual studies, Qin et al. (2023) [<a href="#REF23" class="usa-link" aria-describedby="REF23">23</a>] and Ren et al. (2023) [<a href="#REF22" class="usa-link" aria-describedby="REF22">22</a>] reported OS durations of 15.8 and 13.2 months, respectively, both with tight confidence intervals and highly significant p-values. Pan et al. (2023) [<a href="#REF27" class="usa-link" aria-describedby="REF27">27</a>] reported the highest OS estimate (18.7 months), but with a large standard error, which reduced its weight in the pooled analysis. Clinically, these results suggest that tislelizumab can extend survival in HCC patients by over a year, offering a compelling treatment option for a population with a historically poor prognosis. Given the consistency across studies and the lack of heterogeneity, these findings are reliable and generalizable, supporting broader integration of tislelizumab into HCC treatment protocols.</p>
<figure class="fig xbox font-sm" id="FIG5"><h3 class="obj_head">Figure 5. Forest plot of the pooled analysis on overall survival (OS).</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12335811_cureus-0017-00000087664-i05.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9231/12335811/b62e363c5c2d/cureus-0017-00000087664-i05.jpg" loading="lazy" height="320" width="750" alt="Figure 5"></a></p>
<div class="p text-right font-secondary"><a href="figure/FIG5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>CI: confidence interval</p></figcaption></figure><p>Progression-Free Survival</p>
<p>The forest plot in Figure <a href="#FIG6" class="usa-link">6</a> represents the pooled meta-analysis of the PFS outcomes of tislelizumab in the treatment of HCC across five studies. The fixed-effect model yields a pooled PFS estimate of 4.58 months (95% CI: 3.85-5.31; SE = 0.37), indicating that patients treated with tislelizumab typically experience about 4.6 months without disease progression. This value represents the weighted average duration patients benefit from the treatment before tumor growth or spread occurs. However, the analysis shows substantial heterogeneity (Q = 58.41, df = 4, p &lt; 0.0001), with a very high I² of 93.15%, reflecting significant variability among study outcomes. This heterogeneity is further supported by a high Tau² of 10.78, suggesting the true effects vary considerably across populations and settings. The random-effects model, which accounts for this variability, presents a higher pooled PFS of 5.86 months (95% CI: 2.70-9.02), suggesting some studies observed considerably better outcomes. Among individual studies, Li et al. (2024) [<a href="#REF26" class="usa-link" aria-describedby="REF26">26</a>] and Ren et al. (2023) [<a href="#REF24" class="usa-link" aria-describedby="REF24">24</a>] reported longer PFS durations (11.4 and 8.3 months, respectively), while Qin et al. (2023) [<a href="#REF23" class="usa-link" aria-describedby="REF23">23</a>] and Ren et al. (2023) [<a href="#REF22" class="usa-link" aria-describedby="REF22">22</a>] showed shorter PFS (2.1 and 2.65 months), which significantly influenced overall heterogeneity. Clinically, these findings suggest tislelizumab offers a moderate PFS benefit in HCC, with outcomes varying across patient subgroups. The presence of heterogeneity implies that factors such as tumor burden, prior treatments, and patient immune profiles may significantly affect therapeutic response. These results support its continued use but highlight the importance of patient selection and personalized treatment planning in maximizing clinical benefit.</p>
<figure class="fig xbox font-sm" id="FIG6"><h3 class="obj_head">Figure 6. Forest plot of the pooled analysis on progression-free survival (PFS).</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12335811_cureus-0017-00000087664-i06.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9231/12335811/a2d7333965a7/cureus-0017-00000087664-i06.jpg" loading="lazy" height="343" width="750" alt="Figure 6"></a></p>
<div class="p text-right font-secondary"><a href="figure/FIG6/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>CI: confidence interval</p></figcaption></figure><p>Treatment-Related Adverse Events</p>
<p>The forest plot in Figure <a href="#FIG7" class="usa-link">7</a> illustrates the incidence of Grade ≥ 3 TRAEs associated with tislelizumab in patients with HCC, synthesizing data from six studies. The fixed-effect model yields a pooled logit estimate of -0.458 (95% CI: -0.631 to -0.264; SE = 0.094), which translates approximately to a 28.9% probability of experiencing TRAEs. This suggests that roughly one in three patients undergoing tislelizumab therapy may develop some form of adverse reaction attributable to the treatment. The Z-value of -4.78 (p &lt; 0.000001) confirms the statistical significance of this finding. However, the analysis reveals substantial heterogeneity among studies, with a Q-value of 180.05, df = 5, and I² = 97.2%, indicating that nearly all the variability is due to real differences between studies rather than chance. The Tau² of 2.25 further confirms this inconsistency. As a result, the random-effects model provides a more conservative estimate, with a logit of -1.112, corresponding to a lower probability of adverse events (approximately 24.7%), though the 95% CI crosses zero, reducing its statistical strength. Qin et al. (2023) [<a href="#REF23" class="usa-link" aria-describedby="REF23">23</a>] and Li et al. (2024) [<a href="#REF26" class="usa-link" aria-describedby="REF26">26</a>] contributed substantially to the pooled estimate with significantly negative logits (-2.67 and -3.06), suggesting low TRAE rates. In contrast, Ren et al. (2023) [<a href="#REF22" class="usa-link" aria-describedby="REF22">22</a>] reported a positive logit (0.575), indicating a higher adverse event risk, which contributes to overall heterogeneity. Clinically, these findings underscore that tislelizumab is generally well tolerated, with an acceptable safety profile. However, the high heterogeneity suggests that TRAEs may vary significantly based on population characteristics or clinical context, warranting closer patient monitoring and tailored risk assessments in real-world settings.</p>
<figure class="fig xbox font-sm" id="FIG7"><h3 class="obj_head">Figure 7. Forest plot on the treatment-related adverse events (TRAEs) pooled data.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12335811_cureus-0017-00000087664-i07.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9231/12335811/bfe74da59724/cureus-0017-00000087664-i07.jpg" loading="lazy" height="355" width="750" alt="Figure 7"></a></p>
<div class="p text-right font-secondary"><a href="figure/FIG7/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>GRADE: Grading of Recommendations Assessment, Development, and Evaluation; CI: confidence interval</p></figcaption></figure><p>Publication Bias</p>
<p>Figure <a href="#FIG8" class="usa-link">8</a> shows publication for the tislelizumab meta-analyses on OS, ORR, PFS, and TRAEs using a variety of methods, including Begg and Mazumdar's rank correlation test, Egger's test of the intercept, Duval and Tweedie's trim-and-fill method, and fail-safe N calculations. For OS, Begg's test yielded a non-significant Kendall's tau-b of 0.167 (p = 0.734), and Egger's test showed a non-significant intercept (p = 0.278), suggesting no strong evidence of publication bias. The trim-and-fill method identified one missing study, but the adjusted effect estimate was only slightly lower (13.55 vs. 13.66), indicating a minimal impact. In contrast, ORR analysis revealed signs of publication bias. Egger's test showed a statistically significant intercept (B0 = 7.61, p = 0.027), while Begg's test remained non-significant (tau-b = 0.190, p = 0.548). The trim-and-fill method imputed three missing studies, and the adjusted response rate dropped notably from 22.4% to 17.2%, indicating potential inflation of effect due to small-study bias. For PFS, Begg's (tau-b = 0.100, p = 0.807) and Egger's (B0 = 3.39, p = 0.477) tests were not significant, though the trim-and-fill method detected two missing studies, resulting in a minor decrease in point estimate (from 4.58 to 4.22 months), suggesting limited bias. Finally, for TRAEs, both Begg's (p = 0.707) and Egger's tests (p = 0.251) were non-significant, and the trim-and-fill method suggested no missing studies, affirming the robustness of this safety outcome. In summary, publication bias appears to be minimal for OS, PFS, and TRAE outcomes; however, bias is evident in the ORR estimates, where corrective methods, such as the trim-and-fill method, were applied to adjust the summary effect and ensure validity. These adjustments are crucial for guiding accurate clinical interpretations and evidence-based decision-making.</p>
<figure class="fig xbox font-sm" id="FIG8"><h3 class="obj_head">Figure 8. Funnel plots on publication bias for the included outcomes.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12335811_cureus-0017-00000087664-i08.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9231/12335811/20fd90bc5cf4/cureus-0017-00000087664-i08.jpg" loading="lazy" height="422" width="750" alt="Figure 8"></a></p>
<div class="p text-right font-secondary"><a href="figure/FIG8/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>ORR: objective response rate; OS: overall survival; PFS: progression-free survival; TRAE: treatment-related adverse events</p></figcaption></figure><p>Discussion</p>
<p>This study comprehensively evaluates the clinical efficacy and safety of tislelizumab in treating HCC, providing insights into four key outcomes: ORR, OS, PFS, and TRAEs. For ORR, the fixed-effect model yielded a pooled logit effect size of -1.242, corresponding to an estimated response rate of 22.3%. However, high heterogeneity (I² = 89.93%) and a significant Egger's intercept (p = 0.027) indicate potential publication bias, which is supported by Duval and Tweedie's trim-and-fill analysis, estimating three missing studies. When these were imputed, the ORR dropped to 17.2%, suggesting inflation due to small-study effects. Clinically, while tislelizumab demonstrates a modest anti-tumor response, this may be somewhat overestimated, reinforcing the need for larger, high-quality trials to confirm efficacy. In contrast, OS outcomes were robust. The pooled survival was 13.66 months, with no evidence of heterogeneity (I² = 0%) or bias (Egger's p = 0.278; Begg's p = 0.734). The trim-and-fill adjusted values remained virtually unchanged. This consistency supports a genuine survival benefit, indicating that tislelizumab offers meaningful life extension in HCC patients. For PFS, the pooled estimate was 4.58 months, with high heterogeneity (I² = 93.15%). Although Egger's (p = 0.478) and Begg's tests (p = 0.807) did not indicate publication bias, the trim-and-fill method suggested two missing studies, slightly lowering the PFS to 4.22 months. This implies modest efficacy with potential variations influenced by population or trial factors.</p>
<p>Lastly, the TRAEs logit rate was -0.448, reflecting a 28.9% risk. Despite substantial heterogeneity (I² = 97.2%), no publication bias was found across methods, affirming the acceptable safety profile of tislelizumab. Notably, studies such as Ren et al. (2023) [<a href="#REF24" class="usa-link" aria-describedby="REF24">24</a>], which assessed combination therapies involving ociperlimab and BAT1706 alongside tislelizumab, may have contributed to elevated ORR and PFS estimates. These results likely reflect the additive or synergistic effects of multi-agent regimens and should not be interpreted as representative of tislelizumab monotherapy.</p>
<p>A comparison with the findings of Abushanab et al. [<a href="#REF29" class="usa-link" aria-describedby="REF29">29</a>], who assessed tislelizumab across various malignant solid tumors, offers valuable context. Their pooled analysis reported an HR of 0.71 (95% CI: 0.65-0.78) for OS, aligning with our results and reinforcing the survival benefit of tislelizumab. For PFS, they found an HR of 0.68 (95% CI: 0.54-0.84, p = 0.0005), indicating a similar reduction in disease progression. While their reported ORR was higher (2.59, 95% CI: 2.15-3.12), this likely reflects broader tumor types or combination regimens. Importantly, both studies demonstrated comparable treatment-related adverse event profiles, supporting the drug's favorable safety across indications. Together, these findings affirm tislelizumab's clinical utility, with differences in efficacy outcomes influenced by tumor biology and therapeutic context.</p>
<p>Lin et al.'s [<a href="#REF30" class="usa-link" aria-describedby="REF30">30</a>] analysis of neoadjuvant tislelizumab-based therapy in NSCLC demonstrated a higher pooled incidence of 89% for all-grade TRAEs and 17% for Grade ≥ 3 TRAEs, while our study reported a TRAE incidence of 19% for Grade ≥ 3. This demonstrates the safety profile of the drug in various cancer biology applications, showing similarity.</p>
<p>A comparison with other established immunotherapies, such as nivolumab and atezolizumab, provides important context for evaluating the clinical relevance of tislelizumab in HCC. Tislelizumab, a high-affinity anti-PD-1 antibody with a dissociation constant of 0.15 nmol/L and &gt;90% receptor occupancy at 5 mg/kg, exhibits a half-life of 16.8 days, a clearance of 0.247 L/day, and robust pharmacological activity by activating tumor-infiltrating lymphocytes and inducing superior IFN-γ production compared to nivolumab and pembrolizumab, supporting its clinical evaluation [<a href="#REF6" class="usa-link" aria-describedby="REF6">6</a>,<a href="#REF7" class="usa-link" aria-describedby="REF7">7</a>]. The pooled ORR for tislelizumab was approximately 22.3%, adjusted to 17.2% after accounting for potential publication bias. This response is comparable to that reported in the CheckMate-040 [<a href="#REF31" class="usa-link" aria-describedby="REF31">31</a>] trial, where nivolumab, another PD-1 inhibitor, demonstrated an ORR of 15% in advanced HCC patients post-sorafenib failure [<a href="#REF31" class="usa-link" aria-describedby="REF31">31</a>]. Although slightly lower, the similarity in ORR between the two agents supports the consistent class effect of PD-1 blockade, indicating that tislelizumab provides competitive therapeutic potential as monotherapy.</p>
<p>In terms of OS, tislelizumab showed a pooled estimate of 13.66 months, a result that aligns with the IMbrave150 trial [<a href="#REF32" class="usa-link" aria-describedby="REF32">32</a>], where atezolizumab in combination with bevacizumab achieved a median OS of 13.2 months [<a href="#REF32" class="usa-link" aria-describedby="REF32">32</a>]. Despite the IMbrave150 regimen involving combination therapy and a broader patient base, the comparable survival outcome underscores the potential of tislelizumab to offer significant life extension in HCC patients as a monotherapy. Regarding PFS, tislelizumab yielded a pooled estimate of 4.58 months (random effects: 5.86 months), whereas atezolizumab plus bevacizumab achieved a median of 6.8 months. While this favors combination regimens, tislelizumab still offers meaningful disease control. TRAEs occurred in 28.9% of tislelizumab-treated patients, comparable to nivolumab (19%) and atezolizumab-based regimens (30%) [<a href="#REF31" class="usa-link" aria-describedby="REF31">31</a>,<a href="#REF32" class="usa-link" aria-describedby="REF32">32</a>], confirming a manageable safety profile. Collectively, these comparisons reinforce tislelizumab's viability as a monotherapy option, especially where combination therapies may not be appropriate due to cost, comorbidities, or tolerability concerns.</p>
<p>The study on tislelizumab for HCC faces several limitations. First, significant heterogeneity exists among study populations, with variations in patient demographics, tumor stages, and prior treatments, limiting the generalizability of the findings. Second, the inclusion of both RCTs and observational studies introduces methodological variability, which impacts the robustness of the pooled outcomes. Third, moderate to high risks of bias in areas such as confounding and outcome measurement reduce the reliability of the results, particularly in non-randomized studies. Fourth, small sample sizes in several included studies lower the statistical power and precision of the meta-analysis. Fifth, publication bias is evident in some outcomes, particularly the ORR and TRAEs, which could overestimate the drug's efficacy or safety. Sixth, a lack of long-term follow-up in most studies prevents an assessment of tislelizumab's sustained efficacy and safety. Lastly, variations in how key outcomes are defined and measured, such as tumor responses and adverse events, hinder direct comparisons and the drawing of robust conclusions. Addressing these limitations in future research is crucial to validate the findings and optimize the clinical use of tislelizumab.</p>
<p>Future studies on tislelizumab for HCC should address the limitations of current research to enhance its clinical applicability. First, larger, multicenter RCTs with diverse populations are needed to improve the generalizability of findings and reduce variability caused by demographic and clinical heterogeneity. Ensuring consistent patient inclusion criteria, such as tumor stage and prior treatments, can also enhance the comparability of results across studies. Second, standardized definitions and measurements for key outcomes, such as tumor responses, PFS, and TRAEs, should be adopted to ensure reliable meta-analytical conclusions. Long-term follow-up data are crucial to evaluate the durability of tislelizumab's therapeutic effects and safety profile. Third, advanced statistical techniques, such as subgroup analyses and propensity score matching, could help identify patient subgroups that may derive the most benefit, aiding personalized treatment approaches. Addressing publication bias through pre-registration of clinical trials and transparent reporting of all results, including non-significant findings, is essential. Finally, exploring tislelizumab's efficacy in combination with other therapies, such as targeted agents or radiotherapy, could unlock synergistic effects and broaden its therapeutic potential. Incorporating real-world evidence will further enhance the understanding of its effectiveness and safety in routine clinical practice.</p></section><section id="sec3"><h2 class="pmc_sec_title">Conclusions</h2>
<p>This meta-analysis provides a comprehensive evaluation of tislelizumab's clinical performance in the treatment of HCC across four critical endpoints: ORR, OS, PFS, and TRAEs. The pooled ORR using the fixed-effect model was 22.3% (logit = -1.242, SE = 0.0897), indicating a modest but clinically meaningful tumor response. However, evidence of publication bias was detected through Egger's test (p = 0.027) and confirmed by the trim-and-fill method, which adjusted the ORR downward to 17.2%, suggesting some inflation due to small-study effects. Despite this, the response rate remains within the range of similar PD-1 inhibitors like nivolumab, which has shown a 15% ORR in similar patient populations. The OS analysis yielded a robust pooled estimate of 13.66 months (95% CI: 11.97-15.35), with no heterogeneity (I² = 0%) or publication bias (Egger's p = 0.278), reinforcing the reliability of this outcome. This is on par with or even favorable to survival results from combination regimens such as atezolizumab plus bevacizumab in the IMbrave150 trial (13.2 months), supporting tislelizumab's clinical value even as monotherapy. For PFS, the fixed-effect estimate was 4.58 months (CI: 3.85-5.31), increasing to 5.86 months under the random-effects model. However, high heterogeneity (I² = 93.15%) and modest bias (due to two studies imputing values) suggest response variability across subpopulations. Meanwhile, the incidence of Grade ≥ 3 TRAEs was estimated at 28.9% (logit = -0.448), aligning closely with safety profiles of nivolumab and atezolizumab, and with no evidence of publication bias detected.</p>
<p>Clinically, these results confirm that tislelizumab is an effective and well-tolerated immunotherapy option for HCC, particularly valuable in patients who are unsuitable for combination therapies. Its performance in survival and tolerability outcomes demonstrates meaningful clinical benefit, while observed heterogeneity in response outcomes highlights the need for stratified treatment approaches. Future large-scale trials and real-world studies should further refine patient selection criteria to maximize the therapeutic impact of tislelizumab in the treatment of advanced HCC.</p></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgments</h2>
<p>The authors gratefully acknowledge Dr. Hariharasudhan for his critical intellectual and methodological contributions to this systematic review and meta-analysis. Although listed as the third author, Dr. Hariharasudhan is rightfully recognized as a co-first author in acknowledgment of his significant input throughout the study. He played a key role in conceptualizing the research framework, optimizing the literature search strategy, and providing vital clinical insights during the data interpretation phase. His expert guidance in refining the risk of bias assessments and ensuring statistical robustness was instrumental to the study's credibility. Dr. Hariharasudhan also provided detailed revisions of the manuscript draft, strengthening the scientific presentation and discussion. His commitment to quality and rigor greatly enhanced the overall scholarly value of this work. The team deeply appreciates his collegiality, mentorship, and dedication, without which this publication would not have achieved its current depth and standard.</p></section><section id="app1" class="app"><h2 class="pmc_sec_title">Appendices</h2>
<p>GRADE assessment</p>
<section class="tw xbox font-sm" id="TAB3"><h3 class="obj_head">Table 3. GRADE assessment.</h3>
<div class="caption p"><p>GRADE: Grading of Recommendations Assessment, Development, and Evaluation</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups"><tbody>
<tr style="background-color:#ccc">
<td rowspan="1" colspan="1">
Study
</td>
<td rowspan="1" colspan="1">
Design
</td>
<td rowspan="1" colspan="1">
Risk of Bias
</td>
<td rowspan="1" colspan="1">
Inconsistency
</td>
<td rowspan="1" colspan="1">
Indirectness
</td>
<td rowspan="1" colspan="1">
Imprecision
</td>
<td rowspan="1" colspan="1">
Publication Bias
</td>
<td rowspan="1" colspan="1">
Overall GRADE
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
Ren et al. 2022 [<a href="#REF22" class="usa-link" aria-describedby="REF22">22</a>]
</td>
<td rowspan="1" colspan="1">
Non-randomized phase 2
</td>
<td rowspan="1" colspan="1">
Moderate: open-label design with no comparator
</td>
<td rowspan="1" colspan="1">
Serious: potential variability across 8 countries
</td>
<td rowspan="1" colspan="1">
No: direct HCC population
</td>
<td rowspan="1" colspan="1">
Moderate: large N, but low female %
</td>
<td rowspan="1" colspan="1">
Possible: non-randomized
</td>
<td rowspan="1" colspan="1">
Low
</td>
</tr>
<tr style="background-color:#ccc">
<td rowspan="1" colspan="1">
Qin et al. 2023 [<a href="#REF23" class="usa-link" aria-describedby="REF23">23</a>]
</td>
<td rowspan="1" colspan="1">
Randomized phase 3
</td>
<td rowspan="1" colspan="1">
Low: high-quality RCT
</td>
<td rowspan="1" colspan="1">
No: consistent reporting
</td>
<td rowspan="1" colspan="1">
No: directly applicable
</td>
<td rowspan="1" colspan="1">
Low: large sample (n=674)
</td>
<td rowspan="1" colspan="1">
Unlikely: well-powered RCT
</td>
<td rowspan="1" colspan="1">
High
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
Ren et al. 2023 [<a href="#REF24" class="usa-link" aria-describedby="REF24">24</a>]
</td>
<td rowspan="1" colspan="1">
Randomized phase 2
</td>
<td rowspan="1" colspan="1">
Moderate: small sample, open-label
</td>
<td rowspan="1" colspan="1">
Serious: multiple arms with different drugs
</td>
<td rowspan="1" colspan="1">
Yes: combination therapy limits generalizability
</td>
<td rowspan="1" colspan="1">
Serious: n=94
</td>
<td rowspan="1" colspan="1">
Possible: limited geographic scope
</td>
<td rowspan="1" colspan="1">
Low to Moderate
</td>
</tr>
<tr style="background-color:#ccc">
<td rowspan="1" colspan="1">
Li Z et al. 2023 [<a href="#REF25" class="usa-link" aria-describedby="REF25">25</a>]
</td>
<td rowspan="1" colspan="1">
Phase 1b, single center
</td>
<td rowspan="1" colspan="1">
Serious: very small sample, no control
</td>
<td rowspan="1" colspan="1">
Serious: exploratory in early-stage HCC
</td>
<td rowspan="1" colspan="1">
Yes: population differs (early-stage, not advanced HCC)
</td>
<td rowspan="1" colspan="1">
Serious: very low N=20
</td>
<td rowspan="1" colspan="1">
Likely: early-phase, single-site
</td>
<td rowspan="1" colspan="1">
Very Low
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
Li J et al. 2024 [<a href="#REF26" class="usa-link" aria-describedby="REF26">26</a>]
</td>
<td rowspan="1" colspan="1">
Single-arm phase II
</td>
<td rowspan="1" colspan="1">
Moderate: no control group
</td>
<td rowspan="1" colspan="1">
Serious: unique combination therapy
</td>
<td rowspan="1" colspan="1">
Yes: indirect comparison due to added agents
</td>
<td rowspan="1" colspan="1">
Moderate: n=47
</td>
<td rowspan="1" colspan="1">
Possible: single-center design
</td>
<td rowspan="1" colspan="1">
Low
</td>
</tr>
<tr style="background-color:#ccc">
<td rowspan="1" colspan="1">
Pan et al. 2024 [<a href="#REF27" class="usa-link" aria-describedby="REF27">27</a>]
</td>
<td rowspan="1" colspan="1">
Single-arm phase 2
</td>
<td rowspan="1" colspan="1">
Moderate: lacks control
</td>
<td rowspan="1" colspan="1">
Serious: limited generalizability (macrovascular invasion)
</td>
<td rowspan="1" colspan="1">
Yes: special subset of HCC
</td>
<td rowspan="1" colspan="1">
Serious: n=30
</td>
<td rowspan="1" colspan="1">
Possible: small size
</td>
<td rowspan="1" colspan="1">
Very Low to Low
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
Xu et al. 2024 [<a href="#REF28" class="usa-link" aria-describedby="REF28">28</a>]
</td>
<td rowspan="1" colspan="1">
Single-arm phase 2
</td>
<td rowspan="1" colspan="1">
Moderate: open-label, no comparator
</td>
<td rowspan="1" colspan="1">
Moderate: homogeneous Chinese population
</td>
<td rowspan="1" colspan="1">
No: applicable population
</td>
<td rowspan="1" colspan="1">
Moderate: n=64
</td>
<td rowspan="1" colspan="1">
Possible: limited geography
</td>
<td rowspan="1" colspan="1">
Low to Moderate
</td>
</tr>
</tbody></table></div>
<div class="p text-right font-secondary"><a href="table/TAB3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Disclosures</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn1">
<p><strong>Conflicts of interest:</strong> In compliance with the ICMJE uniform disclosure form, all authors declare the following:</p>
<p><strong>Payment/services info:</strong> All authors have declared that no financial support was received from any organization for the submitted work.</p>
<p><strong>Financial relationships:</strong> All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.</p>
<p><strong>Other relationships:</strong> All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</p>
</div></div></section><section id="fn-group2" class="fn-group"><h2 class="pmc_sec_title">Author Contributions</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn2">
<p><strong>Concept and design:</strong>  Chao Yuan Li Cai, Abigail Rai, Hariharasudhan Balaji, Shyam Nikethen Girivasan, Samuel Rai, Arvin Raju, Shruthi Murugan</p>
<p><strong>Acquisition, analysis, or interpretation of data:</strong>  Chao Yuan Li Cai, Abigail Rai, Hariharasudhan Balaji, Samuel Rai, Arvin Raju, Shruthi Murugan</p>
<p><strong>Drafting of the manuscript:</strong>  Chao Yuan Li Cai, Abigail Rai, Hariharasudhan Balaji, Shyam Nikethen Girivasan, Arvin Raju</p>
<p><strong>Critical review of the manuscript for important intellectual content:</strong>  Chao Yuan Li Cai, Abigail Rai, Hariharasudhan Balaji, Samuel Rai, Shruthi Murugan</p>
<p><strong>Supervision:</strong>  Chao Yuan Li Cai, Abigail Rai, Hariharasudhan Balaji, Shyam Nikethen Girivasan</p>
</div></div></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="ref-list1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="REF1">
<span class="label">1.</span><cite>Asafo-Agyei KO, Samant H. StatPearls [Internet] Treasure Island (FL): StatPearls Publishing; 2024. Hepatocellular carcinoma.</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/32644603/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?title=StatPearls%20%5BInternet%5D&amp;publication_year=2024&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF2">
<span class="label">2.</span><cite>Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Ioannou GN, Splan MF, Weiss NS, McDonald GB, Beretta L, Lee SP. Clin Gastroenterol Hepatol. 2007;5:938–945. doi: 10.1016/j.cgh.2007.02.039.</cite> [<a href="https://doi.org/10.1016/j.cgh.2007.02.039" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17509946/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Gastroenterol%20Hepatol&amp;title=Incidence%20and%20predictors%20of%20hepatocellular%20carcinoma%20in%20patients%20with%20cirrhosis&amp;volume=5&amp;publication_year=2007&amp;pages=938-945&amp;pmid=17509946&amp;doi=10.1016/j.cgh.2007.02.039&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF3">
<span class="label">3.</span><cite>Genetic profiling of hepatocellular carcinoma using next-generation sequencing. Schulze K, Nault JC, Villanueva A. J Hepatol. 2016;65:1031–1042. doi: 10.1016/j.jhep.2016.05.035.</cite> [<a href="https://doi.org/10.1016/j.jhep.2016.05.035" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27262756/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Hepatol&amp;title=Genetic%20profiling%20of%20hepatocellular%20carcinoma%20using%20next-generation%20sequencing&amp;volume=65&amp;publication_year=2016&amp;pages=1031-1042&amp;pmid=27262756&amp;doi=10.1016/j.jhep.2016.05.035&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF4">
<span class="label">4.</span><cite>Neoadjuvant checkpoint blockade for cancer immunotherapy. Topalian SL, Taube JM, Pardoll DM. Science. 2020;367 doi: 10.1126/science.aax0182.</cite> [<a href="https://doi.org/10.1126/science.aax0182" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7789854/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32001626/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Neoadjuvant%20checkpoint%20blockade%20for%20cancer%20immunotherapy&amp;volume=367&amp;publication_year=2020&amp;pmid=32001626&amp;doi=10.1126/science.aax0182&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF5">
<span class="label">5.</span><cite>Tislelizumab: a modified anti-tumor programmed death receptor 1 antibody. Zhang L, Geng Z, Hao B, Geng Q. Cancer Control. 2022;29:10732748221111296. doi: 10.1177/10732748221111296.</cite> [<a href="https://doi.org/10.1177/10732748221111296" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9358212/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35926155/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Control&amp;title=Tislelizumab:%20a%20modified%20anti-tumor%20programmed%20death%20receptor%201%20antibody&amp;volume=29&amp;publication_year=2022&amp;pages=10732748221111296&amp;pmid=35926155&amp;doi=10.1177/10732748221111296&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF6">
<span class="label">6.</span><cite>Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors. Desai J, Deva S, Lee JS, et al.  J Immunother Cancer. 2020;8 doi: 10.1136/jitc-2019-000453.</cite> [<a href="https://doi.org/10.1136/jitc-2019-000453" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7295442/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32540858/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Immunother%20Cancer&amp;title=Phase%20IA/IB%20study%20of%20single-agent%20tislelizumab,%20an%20investigational%20anti-PD-1%20antibody,%20in%20solid%20tumors&amp;volume=8&amp;publication_year=2020&amp;pmid=32540858&amp;doi=10.1136/jitc-2019-000453&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF7">
<span class="label">7.</span><cite>Tislelizumab: first approval. Lee A, Keam SJ. Drugs. 2020;80:617–624. doi: 10.1007/s40265-020-01286-z.</cite> [<a href="https://doi.org/10.1007/s40265-020-01286-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32185681/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Drugs&amp;title=Tislelizumab:%20first%20approval&amp;volume=80&amp;publication_year=2020&amp;pages=617-624&amp;pmid=32185681&amp;doi=10.1007/s40265-020-01286-z&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF8">
<span class="label">8.</span><cite>A phase 2 study of tislelizumab in combination with platinum-based chemotherapy as first-line treatment for advanced lung cancer in Chinese patients. Wang Z, Zhao J, Ma Z, et al.  Lung Cancer. 2020;147:259–268. doi: 10.1016/j.lungcan.2020.06.007.</cite> [<a href="https://doi.org/10.1016/j.lungcan.2020.06.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32769013/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lung%20Cancer&amp;title=A%20phase%202%20study%20of%20tislelizumab%20in%20combination%20with%20platinum-based%20chemotherapy%20as%20first-line%20treatment%20for%20advanced%20lung%20cancer%20in%20Chinese%20patients&amp;volume=147&amp;publication_year=2020&amp;pages=259-268&amp;pmid=32769013&amp;doi=10.1016/j.lungcan.2020.06.007&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF9">
<span class="label">9.</span><cite>Efficacy and safety of low-dose nab-paclitaxel plus tislelizumab in elderly patients with previously treated metastatic non-small cell lung cancer. Zhu W, Geng Q, Peng H, et al.  Front Oncol. 2022;12:802467. doi: 10.3389/fonc.2022.802467.</cite> [<a href="https://doi.org/10.3389/fonc.2022.802467" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8968868/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35372004/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Oncol&amp;title=Efficacy%20and%20safety%20of%20low-dose%20nab-paclitaxel%20plus%20tislelizumab%20in%20elderly%20patients%20with%20previously%20treated%20metastatic%20non-small%20cell%20lung%20cancer&amp;volume=12&amp;publication_year=2022&amp;pages=802467&amp;pmid=35372004&amp;doi=10.3389/fonc.2022.802467&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF10">
<span class="label">10.</span><cite>Short-term and long-term efficacy and safety of pemetrexed and tislelizumab in advanced epidermal growth factor receptor tumor protein 53 co-variant lung adenocarcinoma. Li L, Zhu Y, Lu W, Lin W, Guo N, Chen M. Indian J Pharm Sci. 2022;84:92–96.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Indian%20J%20Pharm%20Sci&amp;title=Short-term%20and%20long-term%20efficacy%20and%20safety%20of%20pemetrexed%20and%20tislelizumab%20in%20advanced%20epidermal%20growth%20factor%20receptor%20tumor%20protein%2053%20co-variant%20lung%20adenocarcinoma&amp;volume=84&amp;publication_year=2022&amp;pages=92-96&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF11">
<span class="label">11.</span><cite>The safety and efficacy of tislelizumab, alone or in combination with chemotherapy, for the treatment of non-small cell lung cancer: a systematic review of clinical trials. Daei Sorkhabi A, ZareDini M, Fazlollahi A, et al.  BMC Pulm Med. 2023;23:495. doi: 10.1186/s12890-023-02755-3.</cite> [<a href="https://doi.org/10.1186/s12890-023-02755-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10704633/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38066549/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Pulm%20Med&amp;title=The%20safety%20and%20efficacy%20of%20tislelizumab,%20alone%20or%20in%20combination%20with%20chemotherapy,%20for%20the%20treatment%20of%20non-small%20cell%20lung%20cancer:%20a%20systematic%20review%20of%20clinical%20trials&amp;volume=23&amp;publication_year=2023&amp;pages=495&amp;pmid=38066549&amp;doi=10.1186/s12890-023-02755-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF12">
<span class="label">12.</span><cite>Notice on the release of drug approval documents on April 13.  [
Nov;
2024 
]. 2020. <a href="https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20200413134101928.html." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20200413134101928.html.</a> <a href="https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20200413134101928.html." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20200413134101928.html.</a></cite>
</li>
<li id="REF13">
<span class="label">13.</span><cite>June 22, 2021, drug approval documents to be received, released-1.  [
Nov;
2024 
]. 2021. <a href="https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20210622215839168.html." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20210622215839168.html.</a> <a href="https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20210622215839168.html." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20210622215839168.html.</a></cite>
</li>
<li id="REF14">
<span class="label">14.</span><cite>Effect of cytokines on advanced hepatocellular carcinoma prognosis receiving radiotherapy and tislelizumab plus anlotinib: a single-center phase II clinical trial. Lin YD, Wu GS, Rao MY, Liu YH, Han YW, Zhang J, Zhang JW. Sci Rep. 2024;14:11486. doi: 10.1038/s41598-024-62523-z.</cite> [<a href="https://doi.org/10.1038/s41598-024-62523-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11106273/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38769368/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Sci%20Rep&amp;title=Effect%20of%20cytokines%20on%20advanced%20hepatocellular%20carcinoma%20prognosis%20receiving%20radiotherapy%20and%20tislelizumab%20plus%20anlotinib:%20a%20single-center%20phase%20II%20clinical%20trial&amp;volume=14&amp;publication_year=2024&amp;pages=11486&amp;pmid=38769368&amp;doi=10.1038/s41598-024-62523-z&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF15">
<span class="label">15.</span><cite>First-in-human phase I trial of TPST-1120, an inhibitor of PPARα, as monotherapy or in combination with nivolumab, in patients with advanced solid tumors. Yarchoan M, Powderly JD, Bastos BR, et al.  Cancer Res Commun. 2024;4:1100–1110. doi: 10.1158/2767-9764.CRC-24-0082.</cite> [<a href="https://doi.org/10.1158/2767-9764.CRC-24-0082" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11025498/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38551394/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Res%20Commun&amp;title=First-in-human%20phase%20I%20trial%20of%20TPST-1120,%20an%20inhibitor%20of%20PPAR%CE%B1,%20as%20monotherapy%20or%20in%20combination%20with%20nivolumab,%20in%20patients%20with%20advanced%20solid%20tumors&amp;volume=4&amp;publication_year=2024&amp;pages=1100-1110&amp;pmid=38551394&amp;doi=10.1158/2767-9764.CRC-24-0082&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF16">
<span class="label">16.</span><cite>Cost-effectiveness analysis of tislelizumab vs sorafenib as the first-line treatment of unresectable hepatocellular carcinoma. Chen Q, Sun Q, Zhang J, Li B, Feng Q, Liu J. PLoS One. 2024;19:0. doi: 10.1371/journal.pone.0295090.</cite> [<a href="https://doi.org/10.1371/journal.pone.0295090" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10911588/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38437209/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=PLoS%20One&amp;title=Cost-effectiveness%20analysis%20of%20tislelizumab%20vs%20sorafenib%20as%20the%20first-line%20treatment%20of%20unresectable%20hepatocellular%20carcinoma&amp;volume=19&amp;publication_year=2024&amp;pages=0&amp;pmid=38437209&amp;doi=10.1371/journal.pone.0295090&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF17">
<span class="label">17.</span><cite>The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.  [
Oct;
2024 
]. 2021. <a href="https://www.bmj.com/content/372/bmj.n71" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.bmj.com/content/372/bmj.n71</a>. <a href="https://www.bmj.com/content/372/bmj.n71" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.bmj.com/content/372/bmj.n71</a></cite> [<a href="https://doi.org/10.1186/s13643-021-01626-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8008539/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33781348/" class="usa-link">PubMed</a>]</li>
<li id="REF18">
<span class="label">18.</span><cite>GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ. BMJ. 2008;336:924–926. doi: 10.1136/bmj.39489.470347.AD.</cite> [<a href="https://doi.org/10.1136/bmj.39489.470347.AD" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2335261/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18436948/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMJ&amp;title=GRADE:%20an%20emerging%20consensus%20on%20rating%20quality%20of%20evidence%20and%20strength%20of%20recommendations&amp;volume=336&amp;publication_year=2008&amp;pages=924-926&amp;pmid=18436948&amp;doi=10.1136/bmj.39489.470347.AD&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF19">
<span class="label">19.</span><cite>RoB 2: a revised tool for assessing risk of bias in randomised trials. Sterne JA, Savović J, Page MJ, et al.  BMJ. 2019;366:0. doi: 10.1136/bmj.l4898.</cite> [<a href="https://doi.org/10.1136/bmj.l4898" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31462531/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMJ&amp;title=RoB%202:%20a%20revised%20tool%20for%20assessing%20risk%20of%20bias%20in%20randomised%20trials&amp;volume=366&amp;publication_year=2019&amp;pages=0&amp;pmid=31462531&amp;doi=10.1136/bmj.l4898&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF20">
<span class="label">20.</span><cite>ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. Sterne JA, Hernán MA, Reeves BC, et al.  BMJ. 2016;355:0. doi: 10.1136/bmj.i4919.</cite> [<a href="https://doi.org/10.1136/bmj.i4919" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5062054/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27733354/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMJ&amp;title=ROBINS-I:%20a%20tool%20for%20assessing%20risk%20of%20bias%20in%20non-randomised%20studies%20of%20interventions&amp;volume=355&amp;publication_year=2016&amp;pages=0&amp;pmid=27733354&amp;doi=10.1136/bmj.i4919&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF21">
<span class="label">21.</span><cite>Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. McGuinness LA, Higgins JP. Res Synth Methods. 2021;12:55–61. doi: 10.1002/jrsm.1411.</cite> [<a href="https://doi.org/10.1002/jrsm.1411" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32336025/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Res%20Synth%20Methods&amp;title=Risk-of-bias%20VISualization%20(robvis):%20an%20R%20package%20and%20Shiny%20web%20app%20for%20visualizing%20risk-of-bias%20assessments&amp;volume=12&amp;publication_year=2021&amp;pages=55-61&amp;pmid=32336025&amp;doi=10.1002/jrsm.1411&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF22">
<span class="label">22.</span><cite>Tislelizumab in patients with previously treated advanced hepatocellular carcinoma (RATIONALE-208): a multicenter, non-randomized, open-label, phase 2 trial. Ren Z, Ducreux M, Abou-Alfa GK, et al.  Liver Cancer. 2023;12:72–84. doi: 10.1159/000527175.</cite> [<a href="https://doi.org/10.1159/000527175" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9982342/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36872927/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Liver%20Cancer&amp;title=Tislelizumab%20in%20patients%20with%20previously%20treated%20advanced%20hepatocellular%20carcinoma%20(RATIONALE-208):%20a%20multicenter,%20non-randomized,%20open-label,%20phase%202%20trial&amp;volume=12&amp;publication_year=2023&amp;pages=72-84&amp;pmid=36872927&amp;doi=10.1159/000527175&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF23">
<span class="label">23.</span><cite>Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3 randomized clinical trial. Qin S, Kudo M, Meyer T, et al.  JAMA Oncol. 2023;9:1651–1659. doi: 10.1001/jamaoncol.2023.4003.</cite> [<a href="https://doi.org/10.1001/jamaoncol.2023.4003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10557031/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37796513/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Oncol&amp;title=Tislelizumab%20vs%20sorafenib%20as%20first-line%20treatment%20for%20unresectable%20hepatocellular%20carcinoma:%20a%20phase%203%20randomized%20clinical%20trial&amp;volume=9&amp;publication_year=2023&amp;pages=1651-1659&amp;pmid=37796513&amp;doi=10.1001/jamaoncol.2023.4003&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF24">
<span class="label">24.</span><cite>945MO AdvanTIG-206: phase II randomized open-label study of ociperlimab (OCI) + tislelizumab (TIS) + BAT1706 (bevacizumab biosimilar) versus TIS + BAT1706 in patients (pts) with advanced hepatocellular carcinoma (HCC) Ren Z, Huang Y, Guo Y, et al.  Ann Oncol. 2023;34:594.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Oncol&amp;title=945MO%20AdvanTIG-206:%20phase%20II%20randomized%20open-label%20study%20of%20ociperlimab%20(OCI)%20+%20tislelizumab%20(TIS)%20+%20BAT1706%20(bevacizumab%20biosimilar)%20versus%20TIS%20+%20BAT1706%20in%20patients%20(pts)%20with%20advanced%20hepatocellular%20carcinoma%20(HCC)&amp;volume=34&amp;publication_year=2023&amp;pages=594&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF25">
<span class="label">25.</span><cite>Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial. Li Z, Liu J, Zhang B, et al.  Nat Commun. 2024;15:3260. doi: 10.1038/s41467-024-47420-3.</cite> [<a href="https://doi.org/10.1038/s41467-024-47420-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11021407/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38627377/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Commun&amp;title=Neoadjuvant%20tislelizumab%20plus%20stereotactic%20body%20radiotherapy%20and%20adjuvant%20tislelizumab%20in%20early-stage%20resectable%20hepatocellular%20carcinoma:%20the%20Notable-HCC%20phase%201b%20trial&amp;volume=15&amp;publication_year=2024&amp;pages=3260&amp;pmid=38627377&amp;doi=10.1038/s41467-024-47420-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF26">
<span class="label">26.</span><cite>SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer. Li J, Bai Y, Chen Z, et al.  Cancer Immunol Immunother. 2024;73:219. doi: 10.1007/s00262-024-03806-2.</cite> [<a href="https://doi.org/10.1007/s00262-024-03806-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11377389/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39235596/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Immunol%20Immunother&amp;title=SAFFRON-104:%20a%20phase%20Ib/II%20study%20of%20sitravatinib%20alone%20or%20with%20tislelizumab%20in%20advanced%20hepatocellular%20carcinoma%20and%20gastric%20cancer/gastroesophageal%20junction%20cancer&amp;volume=73&amp;publication_year=2024&amp;pages=219&amp;pmid=39235596&amp;doi=10.1007/s00262-024-03806-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF27">
<span class="label">27.</span><cite>Perioperative tislelizumab plus intensity modulated radiotherapy in resectable hepatocellular carcinoma with macrovascular invasion: a phase II trial. Pan H, Zhou L, Cheng Z, et al.  Nat Commun. 2024;15:9350. doi: 10.1038/s41467-024-53704-5.</cite> [<a href="https://doi.org/10.1038/s41467-024-53704-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11522700/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39472470/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Commun&amp;title=Perioperative%20tislelizumab%20plus%20intensity%20modulated%20radiotherapy%20in%20resectable%20hepatocellular%20carcinoma%20with%20macrovascular%20invasion:%20a%20phase%20II%20trial&amp;volume=15&amp;publication_year=2024&amp;pages=9350&amp;pmid=39472470&amp;doi=10.1038/s41467-024-53704-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF28">
<span class="label">28.</span><cite>Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial. Xu L, Chen J, Liu C, et al.  BMC Med. 2024;22:172. doi: 10.1186/s12916-024-03356-5.</cite> [<a href="https://doi.org/10.1186/s12916-024-03356-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11036623/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38650037/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Med&amp;title=Efficacy%20and%20safety%20of%20tislelizumab%20plus%20lenvatinib%20as%20first-line%20treatment%20in%20patients%20with%20unresectable%20hepatocellular%20carcinoma:%20a%20multicenter,%20single-arm,%20phase%202%20trial&amp;volume=22&amp;publication_year=2024&amp;pages=172&amp;pmid=38650037&amp;doi=10.1186/s12916-024-03356-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF29">
<span class="label">29.</span><cite>Efficacy and safety of tislelizumab for malignant solid tumor: a systematic review and meta-analysis of phase III randomized trials. Abushanab AK, Mustafa MT, Mousa MT, Qawaqzeh RA, Alqudah GN, Albanawi RF. Expert Rev Clin Pharmacol. 2023;16:1153–1161. doi: 10.1080/17512433.2023.2274544.</cite> [<a href="https://doi.org/10.1080/17512433.2023.2274544" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37864420/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Expert%20Rev%20Clin%20Pharmacol&amp;title=Efficacy%20and%20safety%20of%20tislelizumab%20for%20malignant%20solid%20tumor:%20a%20systematic%20review%20and%20meta-analysis%20of%20phase%20III%20randomized%20trials&amp;volume=16&amp;publication_year=2023&amp;pages=1153-1161&amp;pmid=37864420&amp;doi=10.1080/17512433.2023.2274544&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF30">
<span class="label">30.</span><cite>EP.08D.09 Efficacy and safety of neoadjuvant tislelizumab plus chemotherapy for the treatment of non-small cell lung cancer: a pooled analysis. Lin Y-B, Ding L-R, Wang P-L, et al.  J Thorac Oncol. 2024;19:571–572.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Thorac%20Oncol&amp;title=EP.08D.09%20Efficacy%20and%20safety%20of%20neoadjuvant%20tislelizumab%20plus%20chemotherapy%20for%20the%20treatment%20of%20non-small%20cell%20lung%20cancer:%20a%20pooled%20analysis&amp;volume=19&amp;publication_year=2024&amp;pages=571-572&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF31">
<span class="label">31.</span><cite>Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. El-Khoueiry AB, Sangro B, Yau T, et al.  Lancet. 2017;389:2492–2502. doi: 10.1016/S0140-6736(17)31046-2.</cite> [<a href="https://doi.org/10.1016/S0140-6736(17)31046-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7539326/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28434648/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Nivolumab%20in%20patients%20with%20advanced%20hepatocellular%20carcinoma%20(CheckMate%20040):%20an%20open-label,%20non-comparative,%20phase%201/2%20dose%20escalation%20and%20expansion%20trial&amp;volume=389&amp;publication_year=2017&amp;pages=2492-2502&amp;pmid=28434648&amp;doi=10.1016/S0140-6736(17)31046-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF32">
<span class="label">32.</span><cite>Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. Finn RS, Qin S, Ikeda M, et al.  N Engl J Med. 2020;382:1894–1905. doi: 10.1056/NEJMoa1915745.</cite> [<a href="https://doi.org/10.1056/NEJMoa1915745" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32402160/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Atezolizumab%20plus%20bevacizumab%20in%20unresectable%20hepatocellular%20carcinoma&amp;volume=382&amp;publication_year=2020&amp;pages=1894-1905&amp;pmid=32402160&amp;doi=10.1056/NEJMoa1915745&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Cureus are provided here courtesy of <strong>Cureus Inc.</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.7759/cureus.87664"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/cureus-0017-00000087664.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (3.1 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12335811/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12335811/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12335811%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12335811/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12335811/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12335811/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40786397/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12335811/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40786397/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12335811/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12335811/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="FuewUbovJA3Vp5vIIENV1Gep6VaRlaFhefOMbjgD6IzY1CUkFCW79ZaVU4IWU6Pj">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Web Policies

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    FOIA

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS Vulnerability Disclosure

    
</a>

                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Help

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Accessibility

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Careers

    
</a>

                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NLM

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NIH

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    USA.gov

    
</a>

                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-370d5dd6.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-917ba005.js"></script>
    
    

    </body>
</html>
